Show simple item record

dc.contributor.authorBrewer, Carole
dc.date.accessioned2020-01-10T16:36:41Z
dc.date.available2020-01-10T16:36:41Z
dc.date.issued2019-12
dc.identifier.citationPage EC [et al]. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. European Urology. 2019 Dec;76(6):831-842en_US
dc.identifier.pmid31537406
dc.identifier.doi10.1016/j.eururo.2019.08.019
dc.identifier.urihttps://rde.dspace-express.com/handle/11287/621180
dc.description.abstractMutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0302-2838(19)30668-2en_US
dc.rightsThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.::Geneticsen_US
dc.subjectWessex Classification Subject Headings::Urologyen_US
dc.titleInterim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriersen_US
dc.typeJournal Articleen_US
dc.identifier.journalEuropean Urologyen_US
dc.identifier.pmcidPMC6880781
dc.description.noteThis article is freely available via Open Access. Click on the Publisher URL to access the full-text.en_US
dc.type.versionPublisheden_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).